A Phase 2 interventional study of LUM-201 in Growth Hormone Deficiency, sponsored by Lumos Pharma. Completed at 10 sites in 2 countries. Open to participants aged 3 Years to 13 Years. Per ClinicalTrials.gov, last updated 2026-05-15.
Sponsored by Lumos Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Dwarfism, Pituitary with a site in United States — 11 open to participants now, 12 under way, 3 of them phase 3. Dwarfism, Pituitary · United States.
Among the 89 studies in Dwarfism, Pituitary with a site in United States, this one is the 56th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2022, is one of 15 in phase 2, and was the 81st registered.
252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.
Browse Dwarfism, Pituitary studies →11 of the 89 studies in Dwarfism, Pituitary with a site in United States are open now. Recruiting first, the newest first:
Lumos Pharma · Sites in United States, Argentina, Australia and 5 more countries
Ages 3–11
VA Office of Research and Development · Sites in United States
Ages 21–55
Baylor College of Medicine · Sites in United States
Ages 18–64
Columbia University · Sites in United States
Ages 18–45 · Healthy volunteers
Ascendis Pharma Endocrinology Division A/S · Sites in United States
Ages 1–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.
This study: 3 Years to 13 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 24 · Phase 4 10
First in 1993; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 60 across 169 interventional studies indexed under Dwarfism, Pituitary.
Median enrollment 49 across the 66 interventional studies, 27 across the 21 observational. Of the 74 that completed or were terminated, 33 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 89 have an industry lead sponsor. The 10 most frequent:
This study is registered under Lumos Pharma, one of the names counted as Lumos Pharma, Inc.. Under that name alone:
Lumos Pharma is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Lumos Pharma, Inc. has 6 studies filed under Dwarfism, Pituitary — fewer than ten, so there is no comparison to draw.
2 of the studies in Dwarfism, Pituitary with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04867317Phase 3VA Office of Research and DevelopmentGrowth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD) | 2027-02-28 |
| NCT05355272Baylor College of MedicineGrowth Hormone Replacement in Veterans With GWI and AGHD (GWIT) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 89 studies in Dwarfism, Pituitary with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-national trial. The goals of the trial are to study the growth response to LUM-201 administration in children with idiopathic growth hormone deficiency (GHD) previously treated with daily rhGH for 12 months in the LUM-201-01 trial.
This trial will have one screening/baseline visit with tests to assess if subjects are eligible to start study therapy. The screening/baseline visit can coincide with the Month 12 visit in the LUM-201-01 trial. Subjects will receive the same dose of LUM-201 as a daily oral dose each morning. LUM-201 will be adjusted for body weight increments at each clinic visit, as applicable.
The trial consists of 12 months of treatment. After screening, subjects will return to the clinic for 5 visits. During four of these clinic visits, safety laboratory samples will be collected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: LUM-201
Administered orally once daily
Annualized Height Velocity (AHV) Measured as Standing Height With Stadiometer
Mean change from day 1 to month 12, Annualized Height Velocity (AHV) Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 12 t1 = day 1 t2 = month 12
Time frame: Day 1 to Month 12
Occurrence of Adverse Events in Children With Growth Hormone Deficiency (GHD)
Number of events
Time frame: Day 1 to Month 12
Growth Hormone (GH) Values
Mean GH Values change from Day 1 to month 12 (Pre-Dose and 1 hour Post-Dose)
Time frame: Day 1 to Month 12
Insulin-Like Growth Factor 1 (IGF-1) Values
Mean change from Day 1 to month 12 (IGF-1 Values Pre-Dose)
Time frame: Day 1 to Month 12
Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Values
Mean change from day 1 to month 12 (IGFBP-3 Values Pre-Dose)
Time frame: Day 1 to Month 12
Height (HT) Standard Deviation Score (SDS)
Mean change from day 1 to month 12 in HT-SDS
Time frame: Day 1 to Month 12
Change in Weight
Mean change in Weight from day 1 to month 12
Time frame: Day 1 to Month 12
Change in Weight - Standard Deviation Score (SDS)
Mean change in Weight-SDS from day 1 to month 12
Time frame: Day 1 to Month 12
Change in Body Mass Index (BMI)
Mean change from day 1 to month 12 in BMI
Time frame: Day 1 to Month 12
Change in Body Mass Index (BMI) - Standard Deviation Score (SDS)
Mean change from Day 1 to month 12 in BMI-SDS
Time frame: Day 1 to Month 12
Change in Bone Age
Mean change from day 1 to month 6 in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas
Time frame: Month 6
Insulin-Like Growth Factor 1 (IGF-1) - Standard Deviation Score (SDS)
Mean Change from day 1 to month 12 for IGF-1 - SDS Pre-dose Values
Time frame: Day 1 to Month 12
| Milestone | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Started | 15 |
| Completed | 13 |
| Not completed | 2 |
Mean change from day 1 to month 12, Annualized Height Velocity (AHV) Height is measured in triplicate, by a calibrated stadiometer and taking the mean value AVH equation is (h2-h1/t2-t1)\*365.25; h1 = height measured at day 1 h2 = height measured at month 12 t1 = day 1 t2 = month 12
| cm/year | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Annualized Height Velocity (AHV) Measured as Standing Height With Stadiometer | 0.098 ± 0.775 |
Number of events
| occurences | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Occurrence of Adverse Events in Children With Growth Hormone Deficiency (GHD) | 42 |
Mean GH Values change from Day 1 to month 12 (Pre-Dose and 1 hour Post-Dose)
| ng/ml | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Month 12, Pre-Dose | -0.05 ± 0.68 |
| Month 12, 1 hour Post-Dose | 1.17 ± 2.81 |
Mean change from Day 1 to month 12 (IGF-1 Values Pre-Dose)
| nmol/L | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Insulin-Like Growth Factor 1 (IGF-1) Values | -8.75 ± 14.59 |
Mean change from day 1 to month 12 (IGFBP-3 Values Pre-Dose)
| nmol/L | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Insulin-Like Growth Factor Binding Protein 3 (IGFBP-3) Values | -58.033 ± 33.092 |
Mean change from day 1 to month 12 in HT-SDS
| Standard Deviation Score | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Height (HT) Standard Deviation Score (SDS) | 0.08229 ± 0.20574 |
Mean change in Weight from day 1 to month 12
| kg | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Change in Weight | 4.19 ± 1.74 |
Mean change in Weight-SDS from day 1 to month 12
| Standard Deviation Score | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Change in Weight - Standard Deviation Score (SDS) | 0.62279 ± 0.30934 |
Mean change from day 1 to month 12 in BMI
| kg/m^2 | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Change in Body Mass Index (BMI) | 0.969 ± 0.695 |
Mean change from Day 1 to month 12 in BMI-SDS
| Standard Deviation Score | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Change in Body Mass Index (BMI) - Standard Deviation Score (SDS) | 0.32057 ± 0.30768 |
Mean change from day 1 to month 6 in bone age, measured by X-ray of left hand and wrist using Greulich \& Pyle atlas
| year | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Change in Bone Age | 2.01 ± 0.81 |
Mean Change from day 1 to month 12 for IGF-1 - SDS Pre-dose Values
| Standard Deviation Score | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Insulin-Like Growth Factor 1 (IGF-1) - Standard Deviation Score (SDS) | -1.1083 ± 1.1529 |
Collected over 1 year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LUM-201 (3.2 mg/kg/Day) | 0/15 (0%) | 0/15 (0%) | 13/15 (86.7%) |
| Event | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Upper respiratory tract infectionsInfections and infestations | 3/15 |
| InfluenzaInfections and infestations | 2/15 |
| PharyngitisInfections and infestations | 2/15 |
| Increased appetiteMetabolism and nutrition disorders | 2/15 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 2/15 |
| RashSkin and subcutaneous tissue disorders | 2/15 |
| Abdominal pain upperGastrointestinal disorders | 1/15 |
| PyrexiaGeneral disorders | 1/15 |
| Drug hypersensitivityImmune system disorders | 1/15 |
| BronchitisInfections and infestations | 1/15 |
| Age, Categorical(Participants) | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| <=18 years | 15 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(months) | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Mean | 102 ± 25.5 |
| Sex: Female, Male(Participants) | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Female | 6 |
| Male | 9 |
| Race (NIH/OMB)(Participants) | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 14 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| United States | 9 |
| Poland | 6 |
| Baseline Height-Standard Deviation Score (SDS)(Height-SDS) | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Mean | -1.32492 ± 0.37944 |
| Baseline Insulin-like growth factor 1 (IGF-1) SDS(SDS) | LUM-201 (3.2 mg/kg/Day) |
|---|---|
| Mean | 0.9343 ± 1.1716 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Feb 2022 to primary completion in Jan 2025, 35 months.
Results were first posted in Apr 2026, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ibutamoren